Advertisement

Reduced Prevalence of Limited Joint Mobility in Type 1 Diabetes in a U.K. Clinic Population Over a 20-Year Period

  1. John R. Lindsay, MD1,
  2. Laurence Kennedy, MD2,
  3. A. Brew Atkinson, MD1,
  4. Patrick M. Bell, MD1,
  5. Dennis J. Carson, MB3,
  6. David R. McCance, MD1 and
  7. Steven J. Hunter, MD1
  1. 1Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, U.K
  2. 2Division of Endocrinology, Health Sciences Center, University of Florida, Gainesville, Florida
  3. 3Royal Belfast Hospital for Sick Children, Belfast, U.K
  1. Address correspondence and reprint requests to Dr. S.J. Hunter, Consultant Physician, Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Grosvenor Rd., Belfast, BT12 6BA U.K. E-mail: steven.hunter{at}royalhospitals.n-i.nhs.uk

Abstract

OBJECTIVE—Limited joint mobility (LJM), one of the earliest clinically apparent long-term complications of type 1 diabetes, is a risk marker for subsequent microvascular complications. We hypothesize that the prevalence of LJM may have decreased during the past two decades due to improved standards of glycemic control.

RESEARCH DESIGN AND METHODS—A single observer performed a survey in 204 consecutive patients with type 1 diabetes (106 men and 98 women, age 27 ± 1 years, HbA1c 8.3 ± 0.1%, duration of diabetes 14.5 ± 0.8 years, insulin dose 63 ± 2 units/day). We used the same examination method and criteria for assessment of LJM as used by us in an earlier study in 1981–1982.

RESULTS—The prevalence of LJM has fallen from 43 to 23% between the 1980s and 2002 (P < 0.0001). The relative risk for LJM in 2002 compared with the 1981–1982 cohort was 0.53 (0.40 < RR < 0.72, P < 0.0001). The prevalence of LJM was increased with longer duration of diabetes (<10 years, 13%; 10–20 years, 19%; 20–29 years, 30%; >30 years, 65%; P < 0.001). The relative risk for those with a mean HbA1c <7% in 2002 was 0.3 (0.1 < RR < 1.2, P = 0.05) when compared with those with mean HbA1c >7%.

CONCLUSIONS—The present study confirms the hypothesis that the prevalence of LJM is lower than 20 years ago and that improved standards of glycemic control and diabetes care may have contributed to this occurrence. Joint limitation in type 1 diabetes is strongly associated with duration of diabetes. The presence of LJM remains a common and important clinical marker for subsequent microvascular disease and can be a useful clinical tool for identification of patients at increased risk.

Footnotes

  • L.K. has served on an advisory panel for and has received honoraria and consulting fees from Aventis.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted December 8, 2004.
    • Received October 29, 2004.
| Table of Contents
Advertisement